Vascular grafts
Humacyte develops and sells human tissue-based blood vessel products that surgeons can implant to replace or bypass damaged vessels and create access for dialysis.
Customers and revenue model
Humacyte Inc
NASDAQ:HUMA
Humacyte Inc
NASDAQ:HUMA
Price:
0.6171
USD
4.29%
Market Cap:
$166.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently viewed
Price
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Biotechnology
- Headquarters
- United States of America US
- Employees
- 184
- IPO date
- Sep 22, 2020
Humacyte develops and manufactures bioengineered human tissue for use in surgery and trauma care. Its main product is a laboratory-grown vessel made from human cells that can be used to replace or repair damaged blood vessels. The company is focused on giving doctors an off-the-shelf tissue option where the body needs a strong, living conduit rather than a synthetic tube.
The company sells these tissue products to hospitals and other medical providers, usually through the healthcare supply chain and, in some cases, through government or defense-related channels. Its money comes from product sales and from the regulatory and commercial adoption of its tissue platform in different medical uses. Because the product is a manufactured human tissue implant, its value comes from being ready when needed and designed to integrate with the body better than many standard synthetic alternatives.
Humacyte’s business sits between biotech, medical devices, and regenerative medicine. Instead of making drugs that are taken repeatedly, it is building a platform for living, transplantable tissue that can be used in procedures where surgeons need replacement vessels. That makes it different from many healthcare companies: it is trying to create a new category of implantable human tissue that can be produced at scale and sold like a medical product.
